TTC-352 chemical structure
Chemical structureResearch use only
CAT. NO. DC70851Featured

TTC-352

Pack Sizes & Prices

TotalUS$450
We match the best price and quality on market.
Product overview

Description & Application

TTC-352 is a synthetic selective estrogen mimic acts as estrogen receptor (ER) partial agonist for the treatment of endocrine-resistant breast cancer.TTC-352 yields an H-bond with Glu353, allows Asp351-to-helix 12 (H12) interaction, sealing ERα's ligand-binding domain, recruiting E2-enriched coactivators, and triggering rapid ERα-induced unfolded protein response (UPR) and apoptosis.TTC-352 is a less potent full estrogen agonist compared to E2, allowing H12 to seal the LBD, which recruits many E2-enriched coactivators, and induces rapid ERα-mediated UPR and apoptosis.

ParameterValue
Chemical NameUnii-65ilh3Y0MI
CAS No.1607819-68-0
Synonyms65ILH3Y0MI;3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol;3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol;3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol;BDBM50145856;J3.603.123I;2-(4-Hydroxyphenoxy)-3-(4-fluorophenyl)benzo[b]thiophene-6-ol;3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo(b)thiophene-6-ol;3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol;3-(4-fluoro;Unii-65ilh3Y0MI
FormulaC20H13FO3S
M.Wt352.378827810287
SMILESS1C(=C(C2C=CC(=CC=2)F)C2C=CC(=CC1=2)O)OC1C=CC(=CC=1)O
Purity>97%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

TTC-352 is a synthetic selective estrogen mimic acts as estrogen receptor (ER) partial agonist for the treatment of endocrine-resistant breast cancer.TTC-352 yields an H-bond with Glu353, allows Asp351-to-helix 12 (H12) interaction, sealing ERα's ligand-binding domain, recruiting E2-enriched coactivators, and triggering rapid ERα-induced unfolded protein response (UPR) and apoptosis.TTC-352 is a less potent full estrogen agonist compared to E2, allowing H12 to seal the LBD, which recruits many E2-enriched coactivators, and induces rapid ERα-mediated UPR and apoptosis.

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

1. Balkees Abderrahman, et al. Mol Cancer Ther. 2021 Jan;20(1):11-25.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Product documentation

View online datasheetRequest COA / MSDS

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Solution calculator

Related research products

Bazedoxifene chemical structureDC8922

Bazedoxifene

Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment.modulatorPreclinical and clinical studies with bazedoxifene demonstrate more tissue…

View activity & prices
Giredestrant chemical structureDC40118

Giredestrant

Giredestrant (GDC-9545), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant potently competes with estradiol for binding and induces a conformational change…

View activity & prices
Endoxifen chemical structureDC8265

Endoxifen

Endoxifen Z-isomer is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα). Endoxifen inhibits hERG…

View activity & prices
XCT790 chemical structureDC7735

XCT790

XCT-790 is a potent, selective and inverse agonist of estrogen-related receptor alpha(ERRα); induces cell death in chemotherapeutic resistant cancer cells.XCT-790 induced cell death in HepG2 hepatocarcinoma and its…

View activity & prices

Cart

Request quotation